Clindacin B prolong is commonly used to provide localized anti-infective support for addressing symptoms in women with mixed vaginal infections. This fixed-dose combination is generally applied when therapeutic management must address two distinct microbial domains simultaneously: susceptible bacteria (linked to Bacterial Vaginosis, or BV) and fungal organisms (linked to Vaginal Yeast Infections).

This treatment is relevant for addressing acute and recurrent episodes characterized by various disruptive symptoms. These symptoms include intense vaginal itching, localized burning, abnormal discharge patterns, and the associated fishy odor. The medicine is applied in clinical settings that involve acute or unstable symptom patterns, supporting the goal of comprehensive symptomatic improvement.

“This approach is generally applied where symptomatic relief requires clearance of both microbial categories.”

By effectively addressing both elements, the medication contributes to improved day-to-day comfort during symptomatic periods and supports the patient in maintaining a sense of stability when symptoms are more noticeable. This provides supportive relief that helps ease the overall symptom burden.

---

QuickFact Block

Quick Fact: Relief for Key Symptoms	Description
Symptom Resolution	Supports the clearance of bacterial-linked odor and fungal-linked itching/burning.
Use Context	Relevant for acute and recurrent episodes of mixed vaginitis.
Primary Benefit	Contributes to improved comfort and eases the overall symptom load.

Regulatory References

1. Clinical Experience to Assess Safety and Efficacy of Fixed Dose Combination for Mixed Vaginosis

Who Can and Cannot Use Clindacin B Prolong? (Eligibility Profile)

The active ingredient in Clindacin B prolong, Clindamycin, has specific contraindications and restrictions based on official regulatory labeling. This information defines which patient groups are absolutely prohibited from using the medicine and which require special caution or non-recommendation.

Absolute Non-Eligibility (Contraindications)

Individuals must not use this medicine if they have a documented history of:

• Hypersensitivity (allergy) to Clindamycin, Lincomycin (a related antibiotic), or any other component of the formulation.
• Gastrointestinal Disease, specifically regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Restricted or Conditional Use

• Pregnancy and Lactation: Use during the first trimester of pregnancy is generally not recommended due to insufficient data and should only occur if clearly needed. Caution is advised during breastfeeding due to potential infant exposure.
• Age: The vaginal formulation is generally not established for use in pre-menarcheal females (before the start of menstruation).
• Organ Function: Special caution and potential monitoring of drug levels are necessary for patients with severe hepatic (liver) impairment or severe renal (kidney) impairment.

Interactions with other medicines and products

This section outlines the documented interaction patterns for the active ingredients in Clindacin B prolong, strictly based on official government regulatory labeling. Although systemic exposure is limited following vaginal application, the established interaction profile of Clindamycin remains the regulatory reference point for potential risk.

Interaction Category	Officially Documented Effect
Pharmacodynamic Enhancement	Clindamycin possesses intrinsic neuromuscular blocking properties and may potentiate the action of other Neuromuscular Blocking Agents (e.g., Atracurium, Tubocurarine), a significant consideration in surgical settings.
Metabolic Clearance	Co-administration with strong CYP3A4/3A5 inhibitors may increase Clindamycin exposure in plasma. Conversely, strong enzyme inducers (e.g., Rifampicin, certain herbal products) may reduce exposure, potentially compromising effectiveness.
Antagonism / Coagulation	Antagonism is documented in vitro between Clindamycin and Erythromycin, advising against concurrent use. Furthermore, use with Vitamin K Antagonists (e.g., Warfarin) is associated with reports of increased coagulation test values.
Physical Product Restriction	The cream base contains components that can physically weaken latex or rubber products, including condoms and vaginal diaphragms. Avoidance of these barrier products is required during treatment and for a period of five to seven days following the final dose.

Population notes from regulatory documents confirm that the elimination half-life of Clindamycin is increased in patients with both renal and severe hepatic impairment.

Targeted Inhibition of Bacterial Protein Synthesis

This mechanism involves the antibiotic component, Clindamycin, which selectively targets the bacterial 50S ribosomal subunit to prevent the formation of essential proteins required for cell growth and replication. This molecular blockade of the protein synthesis pathway rapidly suppresses the proliferation of susceptible bacteria, resulting in the suppression of the bacterial growth and survival.

---

️ Disruption of Fungal Cell Membrane Structure

The antifungal component, Butoconazole, exerts its action by blocking the key enzyme lanosterol 14-alpha-demethylase (CYP51) in fungal cells. This enzymatic inhibition halts the biosynthesis of ergosterol, a crucial fungal membrane sterol, leading to structural destabilization and increased permeability. The resulting physiological consequence is the functional compromise of the fungal cell, leading to the suppression of its proliferation.

---

Complementary Mechanistic Dual Action

The drug's core strategy relies on the additive action of its two non-overlapping mechanisms, ensuring coverage against the two distinct pathogen classes (bacteria and fungi). This complementary targeting of both the bacterial ribosome and the fungal CYP51 enzyme provides mechanistic coverage against both bacteria and fungi, which may co-exist in the localized environment.

Instruction Map: How to use Clindacin B prolong — Official Administration Guidelines

Administration Scope	Detail
Route of administration	Intravaginal application for localized action.
Dosing schedule	One full applicatorful of the specific cream/gel formulation per application period.
Timing in relation to meals	Not applicable; topical administration.
Age-group administration rules	Use is generally limited to patients who have begun menstruation. Duration may be extended to 7 consecutive days for pregnant patients (2nd and 3rd trimesters), as detailed in component labeling.
Special procedural conditions	The application must be performed preferably at bedtime (qHS) to maximize local retention.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Topical/Localized (Intravaginal).
Frequency pattern	Once daily (consecutive days).
Use-context constraints	Must not be used orally, dermally, or ophthalmically. Patients are advised to avoid the use of other intravaginal products (e.g., tampons) and vaginal intercourse for the duration of the course to ensure treatment integrity.

---

Resulting Procedural Structure

The official protocol establishes a sequence for the short-term course, which typically ranges from 3 to 7 consecutive days:

• The patient fills or uses the applicator to obtain the one-applicatorful unit dose.
• The dose is administered deep into the vagina at bedtime (qHS).
• The application is repeated once daily until the prescribed number of doses is complete.
• Adherence to official constraints is maintained throughout the full course.

Connection to the overall use protocol

The official instructions establish a standardized, localized application protocol that utilizes a single, defined unit dose administered once per day, typically at night. This ensures proper local retention of the fixed-combination product over a short, consecutive course, with explicit constraints governing co-administration and patient activity during the prescribed regimen.

Evidence for Use in Mixed Bacterial and Fungal Infections

Research has evaluated the combination of Butoconazole and Clindamycin Phosphate in studies focusing on mixed vaginal infections in adult populations. These clinical evaluations, primarily designed as non-comparative studies, examined both clinical endpoints, such as changes in outcomes related to physical discomfort (itching and discharge), and microbiological endpoints, such as the measured clearance of the bacterial and fungal organisms. Research describes patterns related to these changes in symptoms and pathogen counts. This evidence is supported by high-level Randomized Controlled Trials (RCTs) that explored the individual active agents (Clindamycin and Butoconazole) for their respective single infections.

Study Strength and Areas of Uncertainty

The evidence for the combination product is categorized as moderate because direct research on the specific formulation is typically derived from smaller, non-comparative studies. Research explored short-term symptom changes with initial assessments measured within the first seven to fourteen days post-therapy. Intermediate-term follow-up often extended up to approximately three months post-treatment, where studies monitored the measured rate of recurrence. There is limited information for long-term outcomes beyond this period. Furthermore, comparative evidence is lacking as foundational studies are non-comparative. The research focuses predominantly on non-pregnant women of reproductive age (18 to 45 years); data for certain groups remain insufficient, including pregnant women, older adults, or those with underlying health conditions.

Key Studies & References

1. Clinical Experience to Assess Safety and Efficacy of Fixed Dose Combination for Mixed Vaginosis

Common questions about Clindacin B prolong (FAQ)

Q: Is Clindacin B prolong an antibiotic medicine?

The product is a dual-action medicine intended to address both bacterial and fungal infections. Official documents confirm that one of the active ingredients, Clindamycin, is classified as a lincosamide antibacterial drug. The antibiotic component is described as inhibiting the growth of susceptible bacteria.

Q: Is the medicine still working if a person does not feel or see an immediate change?

The successful outcome of the treatment is often associated with completing the full course prescribed by a healthcare provider. Regulatory information indicates that stopping treatment early, even if symptoms seem to clear up, may prevent the infection from being completely treated. This indicates that the full therapeutic effect is linked to using the product for the entire prescribed duration.

Q: Is severe diarrhea a known side effect of this medicine?

Diarrhea is a reported side effect of the medicine's antibiotic component. Official prescribing information states that Clindamycin has been linked to severe colitis, including Pseudomembranous Colitis. This serious reaction can potentially involve severe, watery, or bloody diarrhea.

Q: What are the signs of a serious allergic reaction to Clindacin B prolong?

Serious allergic reactions to the medicine have been reported in regulatory documents. Signs can include rash, hives, and difficulty breathing. Additionally, swelling of the hands, face, or mouth, or difficulty swallowing are described as potential signs of a serious reaction.

Q: Does Clindacin B prolong interact with any vitamin, mineral, or herbal supplements?

Regulatory information states that the antibiotic component of the medicine can interact with certain substances. Specifically, co-administration with strong enzyme-inducing substances, which include certain herbal products, may reduce the body's exposure to Clindamycin. This potential interaction may result in reduced effectiveness of the medicine.

Q: How long after starting treatment should a person expect to notice an effect?

The medicine is typically prescribed for a short course of several consecutive days to achieve clearance of the infection. Official guidelines recommend completing the medication for the full prescribed duration. This is considered an important factor in maximizing the likelihood of the infection resolving, even if initial symptom improvement is quick.

Q: Does Clindacin B prolong work immediately after the first use?

The antibiotic component of the medicine, Clindamycin, works by rapidly suppressing the creation of essential bacterial proteins. However, the full clinical benefit and resolution of the infection are typically achieved upon completing the entire course of therapy as prescribed.

Q: Does Clindacin B prolong contain any ingredients that can cause irritation besides the active drug?

Official documents indicate that some clindamycin formulations contain excipients, such as an alcohol base, that are not the active drug. These non-active ingredients may be a factor in local reactions like stinging or burning, particularly when applied to sensitive areas.

Q: What should be done if an unusual change in vaginal discharge is noticed while using it?

Use of the antibiotic component can sometimes lead to the overgrowth of non-susceptible organisms, such as yeast. This overgrowth may result in new or unusual symptoms, such as thick, white vaginal discharge. Official safety information indicates that consultation with a healthcare professional is appropriate if symptoms worsen or if new symptoms appear during treatment.

Q: Are there any known interactions between Clindacin B prolong and birth control pills?

Official drug interaction databases for the antibiotic component indicate that some antibiotics may potentially reduce the effectiveness of hormonal oral contraceptives in certain people. Because of this possibility, individuals using hormonal birth control should review this potential risk with their prescribing doctor.

Q: Can a metallic or unpleasant taste be a temporary side effect of Clindacin B prolong?

An unpleasant or metallic taste has been reported as a side effect following the oral administration of clindamycin. While this product is for local application, the official safety profile often references effects seen with the active ingredient across different formulations.

Q: Does Clindacin B prolong cause increased sensitivity to sunlight or UV light?

Official regulatory information advises minimizing sun exposure and utilizing protective measures, such as sunscreen, following drug application. This guidance indicates a potential risk of photosensitivity, which means the skin may react more easily to sunlight or UV light.

Q: Does the effect of Clindacin B prolong on the digestive system stop immediately after the treatment is finished?

Official regulatory labeling indicates that the effect on the digestive system, including the risk of severe colitis, may not end immediately upon stopping the medicine. Diarrhea and colitis have been observed to begin up to several weeks following the cessation of clindamycin therapy.

Q: Can stopping the full course of treatment early lead to bacterial resistance?

Official drug information emphasizes the importance of completing the full course of treatment and avoiding skipped doses. If the medicine is discontinued too soon, the underlying infection may not be completely treated, and the remaining bacteria may become resistant to antibiotics.

Q: Is it necessary to thoroughly wash and dry the affected area before applying the topical form?

Instructions for similar topical clindamycin products generally recommend cleaning the application site beforehand. This procedure is described as generally including gently washing the affected area with a mild soap, rinsing with warm water, and patting the skin dry prior to application.

Q: What is the advice on what to do if a person misses a dose of Clindacin B prolong?

If a dose is missed, regulatory guidance suggests applying it as soon as the person remembers. If it is almost time for the next scheduled dose, the missed dose is described as being skipped entirely, with the person returning to their regular schedule. Regulatory guidance states that doses should not be doubled.

How to Store and Dispose of Clindacin B prolong?

Storing Clindacin B prolong (Clindamycin/Butoconazole) requires adherence to specific temperature and handling instructions as defined in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). It is essential not to refrigerate and not to freeze the product, as these conditions can compromise the formulation. To maintain integrity, keep the product in its original container, tightly closed, away from excessive moisture and heat. All medicine must be stored out of the sight and reach of children.

Disposal Instructions

Do not throw away unused or expired product in household trash or dispose of it via wastewater (e.g., flushing down the toilet or sink). Disposal must follow a formal protocol; ask a pharmacist how to properly discard the medicine according to local regulations to help protect the environment.